Alkem Laboratories

In 1953, twenty years before the company that carries his name existed, Samprada Singh opened a chemist shop near Patna Medical College Hospital. That shop, and the distribution business it grew into as Magadh Pharma, gave him an unusual commercial education: he learned how Indian doctors prescribe, how distributors move stock and how patients buy, from the dispensing counter outward, not from a strategy deck inward.

In 1973 he and his brother Basudeo Narayan Singh founded Alkem Laboratories in Mumbai. The first manufacturing unit went up at Taloja in 1978; by 2003 the same site had an ANDA-focused R&D facility, a deliberate run-up to the US regulated market.

An anti-infective franchise that became the identity

Alkem's modern identity is an anti-infective story. Taxim became the first Indian anti-infective brand to cross ₹100 crore in domestic sales (2006); Clavam crossed ₹200 crore (2014). Both are standard practice for thousands of GPs, paediatricians and ENT specialists. Few measures of a pharma company are as durable as the brand prescribers reach for without thinking. The US business grew alongside: first ANDA filed 2007 (Amlodipine), approved 2009; US manufacturing acquired 2012 to 2015. By its December 2015 listing Alkem had 21 facilities and about 705 branded generics.

Why the commercial engine is the interesting part

By FY2025 Alkem reports revenue of about ₹12,964 crore on net income of about ₹2,165 crore. Underneath sit two engines under one P&L: a brand-led Indian prescription business (detailing frequency, prescriber relationships, divisional discipline) and an ANDA-led US generics business (filings, inspections, price-erosion management), plus specialty and biosimilar layers via subsidiaries such as Enzene on a different cadence. Keeping each engine performing without slowing the others is the binding constraint.

The next chapter

Samprada Singh died in 2019. The next generation now runs the company. The market's question is less whether the anti-infective franchise is intact (it is) and more whether the chronic-care, specialty and biosimilar layers settle onto a field force that has been anti-infective-coded for two decades.

It will not be more dashboards. The next advantage is intelligence: every rep knowing what shifted in a prescriber's Taxim or Clavam share this fortnight before the call, every divisional head separating a market shift from a detailing-frequency gap, leadership acting on the few decisions that move the quarter. The first generation of Indian pharma built access. The second built scale. The next will build intelligent commercial operations. That is the future PharmaOS is built for.